BCOR and BCORL1 mutations in pediatric acute myeloid leukemia

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10295003" target="_blank" >RIV/00216208:11130/15:10295003 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/15:10295003
Result on the web
<a href="http://dx.doi.org/10.3324/haematol.2014.117796" target="_blank" >http://dx.doi.org/10.3324/haematol.2014.117796</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2014.117796" target="_blank" >10.3324/haematol.2014.117796</a>

Result language
angličtina
Original language name
BCOR and BCORL1 mutations in pediatric acute myeloid leukemia
Original language description
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the presence of different collaborating cytogenetic and molecular aberrations that are associated with treatment response. Approximately 20% of pediatric AML patients are classifiedas cytogenetically normal AML (CN-AML). In the past decade, new prognostic relevant aberrations have been identified in CN-AML, such as NPM1, WT1, FLT3-ITD and CEBPA double mutations (CEBPAdm), which may improve future risk-group stratification. In addition to these mutations, we recently described recurrent cryptic NUP98/NSD1 and NUP98/KDM5A translocations in pediatric CN-AML.9,10 Still, some CN-AML samples have not been fully characterized.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)